 Home > Active Ingredient News > Drugs Articles > Review of China's hospital pharmaceutical market in the third quarter of 2022

Review of China's hospital pharmaceutical market in the third quarter of 2022

 Last Update: 2023-01-05
 Source: Internet
 Author: User

Tags

prolene 4 0

full time jobs cincinnati

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Overall market performance

In the third quarter of 2022, China's hospital pharmaceutical market has recovered, but it still decreased slightly year-on-year, and the total sales* quarterly growth rate was -0.
5% year-on-year [Data source: IQVIA China Hospital Drug Statistics Report, ≥ 100 beds
.
Based on 12-month MAT sales (rolling full-year data)**], total MAT sales in the third quarter of 2022 were flat year-over-year and stable
.

* Sales: Sales of hospitals with more than 100 beds, calculated based on the purchase price of the hospital, the same below

** MAT Sales (Rolling Full Year): The sum of data going back 12 months at a specified point in time, in this case sales from Q4 2021 to Q3 2022

Market performance of multinational and local companies

From the perspective of different business types, the sales of multinational enterprises in the third quarter of 2022 decreased by 3.
6% year-on-year; The sales of local enterprises in the third quarter increased by 0.
7% year-on-year, and the sales performance of multinational enterprises and local enterprises recovered
significantly compared with the previous quarter.
The annual sales of MAT of multinational enterprises decreased by 3.
0% year-on-year; Local MAT annual sales increased by 1.
2%
year-on-year.

Market performance of key therapeutic areas and key products

Looking at all major therapeutic areas, quarterly sales in all categories generally showed a recovery trend in the third quarter of 2022
.
Proprietary Chinese medicines still ranked first in the hospital market, with quarterly sales increasing by 5.
4% year-on-year; MAT's annual sales increased by 5.
5% year-on-year, ranking first in all categories, among which proprietary Chinese medicine products used to treat colds and coughs performed well
.
Anti-tumor and immunomodulators ranked second, with quarterly sales growth declining year-over-year at -1.
6%; MAT's annual sales increased by nearly 1.
3%
year-on-year.
Quarterly sales of digestive tract and metabolism, and systemic anti-infective drugs ranked third and fourth
, respectively.

Looking at the major therapeutic areas

From the perspective of quarterly sales of products, Enbipu continued to maintain the first place, and Shupushen and Garonin ranked second and third respectively
.
Among the top 10 products, 6 products are from multinational enterprises
.
Thanks to the dividends brought by the inclusion of national medical insurance, Andatang has maintained rapid growth, with a year-on-year growth rate of 59.
5%
in MAT.

From the quarterly sales of the product

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.